4//SEC Filing
Cheng Isaac 4
Accession 0000899243-22-001525
CIK 0001658551other
Filed
Jan 9, 7:00 PM ET
Accepted
Jan 10, 8:35 PM ET
Size
23.9 KB
Accession
0000899243-22-001525
Insider Transaction Report
Form 4
Cheng Isaac
Director
Transactions
- Conversion
Common Stock
2022-01-06+974,107→ 8,794,106 total(indirect: See Footnote) - Conversion
Common Stock
2022-01-06+6,410,964→ 7,819,999 total(indirect: See Footnote) - Conversion
Series A Preferred Stock
2022-01-06−1,409,035→ 0 total(indirect: See Footnote)→ Common Stock (1,409,035 underlying) - Conversion
Common Stock
2022-01-06+1,409,035→ 1,409,035 total(indirect: See Footnote) - Conversion
Series C-2 Preferred Stock
2022-01-06−1,621,544→ 0 total(indirect: See Footnote)→ Common Stock (1,621,544 underlying) - Conversion
Common Stock
2022-01-06+1,621,544→ 10,415,650 total(indirect: See Footnote) - Conversion
Series B Preferred Stock
2022-01-06−6,410,964→ 0 total(indirect: See Footnote)→ Common Stock (6,410,964 underlying) - Purchase
Common Stock
2022-01-06$19.00/sh+6,578$124,982→ 6,578 total - Conversion
Series C-1 Preferred Stock
2022-01-06−974,107→ 0 total(indirect: See Footnote)→ Common Stock (974,107 underlying) - Award
Stock Option (Right to Buy)
2022-01-06+8,400→ 8,400 totalExercise: $19.00Exp: 2032-01-06→ Common Stock (8,400 underlying)
Footnotes (3)
- [F1]Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date.
- [F2]These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares.
- [F3]This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Documents
Issuer
Amylyx Pharmaceuticals, Inc.
CIK 0001658551
Entity typeother
Related Parties
1- filerCIK 0001829696
Filing Metadata
- Form type
- 4
- Filed
- Jan 9, 7:00 PM ET
- Accepted
- Jan 10, 8:35 PM ET
- Size
- 23.9 KB